Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report issued on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Price Performance

Shares of NASDAQ EVGN opened at $4.87 on Monday. Evogene has a 12-month low of $4.50 and a 12-month high of $10.90. The company has a market capitalization of $200.72 million, a PE ratio of -10.59 and a beta of 1.40. The firm’s 50-day moving average is $6.34 and its two-hundred day moving average is $7.22.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, May 23rd. The biotechnology company reported ($0.80) earnings per share for the quarter. The firm had revenue of $4.19 million during the quarter. Evogene had a negative net margin of 233.66% and a negative return on equity of 70.96%.

Hedge Funds Weigh In On Evogene

An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets lifted its holdings in Evogene Ltd. (NASDAQ:EVGN) by 30.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the period. BNP Paribas Financial Markets owned approximately 0.22% of Evogene worth $69,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.